July 17th 2020
June 1st 2019
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.
February 19th 2019
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses promising data with acalabrutinib in the treatment of patients with mantle cell lymphoma.
September 5th 2018
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).
August 3rd 2018
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).
July 26th 2018
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).
June 22nd 2018
Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses prognostic markers in mantle cell lymphoma (MCL).
June 13th 2018
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).
May 9th 2018
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolving treatment landscape of mantle cell lymphoma.
April 9th 2018
Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, provides a comparison of acalabrutinib (Calquence) with ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).
April 4th 2018
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the importance of achieving minimal residual disease (MRD) negativity in mantle cell lymphoma (MCL).
March 26th 2018
Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in the treatment of patients with mantle cell lymphoma (MCL).
March 13th 2018
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of patients with mantle cell lymphoma (MCL).
February 20th 2018
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.
January 27th 2018
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combinations in mantle cell lymphoma.
December 12th 2017
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma.